Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Blood|September 3, 2010
Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonistsAditya Mandawat, Warren Fiskus, Kathleen M Buckley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 13, 2018
Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune ChangesAndrew R DiNardo, Tomoki Nishiguchi, Emily M Mace, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumorsCristiana Sessa, Geoffrey I Shapiro, Kapil N Bhalla, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 19, 2021
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin β-Like 1-β-Catenin Protein ComplexRaffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, et al.
Blood Cancer Journal|February 5, 2024
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)Christopher P Mill, Warren C Fiskus, Courtney D DiNardo, et al.
American Journal of Hematology|December 9, 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D DiNardo, Caitlin R Rausch, Christopher Benton, et al.
Breast Cancer Research and Treatment|June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancerYifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Blood Advances|January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosisPrajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
Cancer Cell|October 20, 2012
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.
Pageof 13